主持国家及省部级项目在内的基金项目共10项，获得1项发明专利(排名第1)和5项实用新型专利(其中3项排名第1)。以第一/通讯作者发表SCI论文27篇（总影响因子135分，单篇最高10.9分）。Presided over a total of 10 grants or funds, including national and provincial projects, and obtained one invention patent(rank 1 ) and 5 utility model patents (rank 1 in 3/5). Published 27 papers in SCI journals(total impact factor 135 points, and the highest one is 10.9 points) as the first or correspondent author.
主要基金及科研项目 Main Grants & Foundation
国家自然科学基金面上项目，81972409，2020.01-2023.12，54万，已结题，主持。
National Natural Science Foundation of China (General Program), 8197240, 2020.01-2023.12, RMB540,000, Finished, Presided. National Natural Science Foundation of China
国家自然科学基金面上项目，81672549，2017.01-2020.12，57万，已结题，主持。
National Natural Science Foundation of China (General Program), 81672549, 2017.01-2020.12, RMB570,000. Finished, Presided. National Natural Science Foundation of China
国家自然科学基金面上项目，81472389，2015.01-2018.12，72万，已结题，参加（排名第2）。
National Natural Science Foundation of China (General Program), 81472389, 2015.01-2018.12, RMB720,000, Finished, Participated(Rank 2).
上海市自然科学基金面上项目，15ZR1433000，2015.01-2017.12，10万，已结题，主持。
Natural Science Foundation of Shanghai (General Program), 15ZR1433000, 2015.01-2017.12, RMB100,000. Finished, Presided.
中国博士后科学基金第53批面上资助，2013M531123，2013.06-2014.05，5万，已结题，主持。
China Postdoctoral Science Foundation (General Program), 2013M531123, 2013.06-2014.05, RMB 50,000, Finished, Presided.
上海市博士后科研资助计划面上项目(A类)，12R21411600，2012.06-2013.05，4万，已结题，主持。
Shanghai Postdoctoral Scientific Program (General Program), 12R21411600, 2012.06-2013.05, RMB 40,000, Finished, Presided.
大连市科技计划项目，2004B3SF163，2004.06-2007.05，3万，已结题，主持。
Dalian Municipal Science and Technology Program, 2004B3SF163, 2004.06-2007.05, RMB 30,000, Finished, Presided.
代表性论文（仅列第一作者和通讯作者）
Bibliographies(Only the first & correspondence author)
Xin S#, Zhang Y#, Zhang Z#,Sun X, Li Z, Liu X, Jin L, Li W, Tang C, Mei W, Wang H,Zhou Z, Li R, Wen X, Yang G,Chen W*, Junhua Zheng*, Lin Ye*. ScRNA-seq revealed the tumor microenvironment heterogeneity related to the ocuurence and metastasis in upper urinary tract urothelial carcinoma. Cancer Gene Therapy. 2024.2.29 Revise.
Sun X#, Zhang Y#, Xin S, Jin L, Cao Q, Wang H, Wang K, Liu X, Tang C, Li W, Li Z, Wen Xi, Yang G, Guo C*, Liu Z*, Ye L*. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway. Cancer Science. 2024 Feb;115(2):412-426. doi: 10.1111/cas.16040. Epub 2023 Dec 20.
Xin S#, Liu X#, Li Z, Sun X, Wang R, Zhang Z, Feng X, Jin L, Li W, Tang C, Mei W, Cao Q, Wang H, Zhang J, Feng L*, Ye L*. ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer. Experimental Hematology & Oncology. 2023 May 23;12(1):49. doi: 10.1186/s40164-023-00407-0.
Mei W, Jin L, Zhang B, Sun X, Liu X, Xin S, Zhang J, Yang G, Li S*, Ye L*. A Moonlighting Gene Signature for Prognosis and Immune Microenvironment Estimation in Prostate Cancer. Frontier in Oncology.2022,12:982267.doi: 10.3389/fonc.2022.982267.
Jin L†, Mei W†, Liu X, Sun X, Xin S, Zhou Z, Zhang J, Zhang B, Chen P*,Cai M*, Ye L*. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer. Frontiers in Immunology 2022,13:974034.doi: 10.3389/fimmu.2022.974034.
Liu X, Mei W, Jin L, Sun X, Xin S, Huang L, Yang G, Wang J*, Ye L*. Ubiquitin-related lncRNAs: the new tool for prognosis prediction in prostate cancer. Frontiers in Oncology 2022,12:948113. doi: 10.3389/fonc.2022.948113.
Sun X #, Xin S#, Zhang Y, Jin L, Liu X, Zhang J, Mei W, Zhang B, Ma W*,Ye L*. The long non-coding RNA CASC11 promotes prostate cancer progression via YBX1-mediated suppression of p53 pathway. International Journal of Oncology. 2022 Sep;61(3):110. doi: 10.3892/ijo.2022.5400. Epub 2022 Jul 29.
Sun X#, Zhang Y#, Chen Y#, Xin S, Jin L, Liu X, Zhou Z, Zhang J, Mei W, Zhang B, Yao X*, Yang G*, Ye L*. In silico establishment and validation of novel lipid metabolism related gene signature in bladder cancer. Oxidative Medicine and Cellular Longevity. 2022 Apr 18;2022:3170950. doi: 10.1155/2022/3170950. eCollection 2022.
Sun X#, Zhou Z#, Zhang Y, Wang J, Zhao X, Jin L, Zhai T, Liu X, Zhang J, Mei W, Zhang B, Luo M*, Yao X*, Ye L*. Identification and validation of a hypoxia-related prognostic and immune microenvironment signature in bladder cancer. Cancer Cell International. 2021 May 7;21(1):251. doi: 10.1186/s12935-021-01954-4.
Zhou Z#, Yue F#, Jin L#, Liu X, Zhai T-S, Zhang J-X, Gu W-Y, Liu S-H, Luo M, Peng B, Yao X-D, Ye L*. Characteristics and risk differences of different tumor size on localised prostate cancer: A retrospective cohort study in the SEER database. Cancer Medicine. 2021 Apr;10(8):2763-2773. doi: 10.1002/cam4.3856. Epub 2021 Mar 16.
Zhai T-S, Hu L-T, Ma W-G, Chen X, Luo M, Jin L, Zhou Z, Liu X, Kang Y, Kang Y-X, Zhang J-X, Liu H, Lu J-Y*, Yao X-D*, Ye L*. Peri-prostatic fat measurements using MRI predict prostate cancer aggressiveness in men undergoing radical prostatectomy. Journal of Endocrinological Investigation. 2021 Feb;44(2):287-296. doi: 10.1007/s40618-020-01294-6. Epub 2020 May 30.
Yu Y#, Yang F-H#, Zhang W-T, Guo Y-D, Ye L*, Yao X-D*. Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy. Cell And Bioscience. 2021 Jan 7;11(7). doi: 10.1186/s13578-020-00494-0.
Zhai T-S#, Jin L#, Feng L-M#, Zhou Z, Liu X, Liu H, Ma W-G, Lu J-Y, Chen W, Yao X-D*, Ye L*. Perioperative chemotherapy on survival in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy: A Population-Based Study. Frontiers in Oncology. 2020 Apr 10:481. doi: 10.3389/fonc.2020.00481. eCollection 2020.
Zhai, T-S#, Jin L#, Hu L-T#, Kadier A, Zhou Z, Liu X, Liu H, Li S, Lu J-Y, Yao X-D*, Ye L*. Impact of peri-prostatic fat measurements using MRI on the prediction of prostate cancer with transrectal ultrasound-guided biopsy. Urologic Oncology-Seminars and Original Investigations. 2020 Feb;38(2):37.e1-37.e9.
Ye L#, Yao X-D#, Wan F-N#, Qu Y-Y, Liu Z-Y, Yue F, Shen X-X, Li S, Wang N, Liu X-J, Dai B, Ye D-W*. MS4A8B promotes cell proliferation in prostate cancer. The Prostate. 2014;74(9):911-922.
Ye L#, Li S#, Ye D*, Yang D, Yue F, Guo Y, Chen X, Chen F, Zhang J*, Song X*. Livin expression may be regulated by miR-198 in human prostate cancer cell lines. European Journal of Cancer. 2013, 49(3):734-740.
Ye L, Song X*, Li S, Yang D, Zhang J, Che X, Chen X, Wang J, Zhang Z. Livin-alpha promotes cell proliferation by regulating G1-S cell cycle transition in prostate cancer. The Prostate. 2011, 71(1):42-51.
